Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients

Basit Öğe Kaydı
dc.contributor.authorFusun, T
dc.contributor.authorSemsi, A
dc.contributor.authorCem, U
dc.contributor.authorMevlut, T
dc.contributor.authorZafer, K
dc.contributor.authorKazim, U
dc.contributor.authorSelcuk, B
dc.date.accessioned2024-06-12T10:54:06Z
dc.date.available2024-06-12T10:54:06Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim: To evaluate the prognostic significance of HER-2/neu overexpression in hormone receptor and axillary lymph node positive breast cancer patients treated in a single institution. Methods: Paraffin-embedded primary breast cancers from 40 patients with invasive ductal carcinoma were studied immunohistochemically. HER-2/neu staining was classified as negative (0, 1+), weak/moderate positive (2+), or moderate/strong positive (3+) and was assessed for effectiveness as a predictor of outcome in univariate and Cox model multivariate analyses. Results: 20% of patients were positive for HER-2/neu. Significant associations were observed between HER-2/neu and increasing number of involved nodes (p = 0.014), p53 positivity (p = 0.039), the presence of vascular invasion (p = 0.029) and metastases (p = 0.01). Multivariate analysis demonstrated that HER-2/neu overexpression (p = 0.016) and age (p = 0.005) were independent predictors for disease-free survival (DFS) where the number of involved nodes (p = 0.032) was shown to be independent predictor for overall survival. In the HER-2/neu positively stained tumors, significant number of patients developed distant metastases than the patients with HER-2/neu negatively stained tumors (87.5% vs 34.4%, p = 0.01). Conclusion: For node positive patients, HER-2/neu overexpression was a significant predictor of DFS.en_US
dc.identifier.endpage149en_US
dc.identifier.issn1812-9269
dc.identifier.issue2en_US
dc.identifier.pmid15995634en_US
dc.identifier.scopus2-s2.0-22644435284en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18926
dc.identifier.volume27en_US
dc.identifier.wosWOS:000230711500013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInst Exp Pathol Oncol Radiobiolen_US
dc.relation.ispartofExperimental Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAxillary Lymph Node Involvementen_US
dc.subjectBreast Canceren_US
dc.subjectHER-2/Neuen_US
dc.subjectPrognosisen_US
dc.subjectIn-Situ Hybridizationen_US
dc.subjectPrognostic Valueen_US
dc.subjectP53 Expressionen_US
dc.subjectC-Erbb-2 Overexpressionen_US
dc.subjectGene Amplificationen_US
dc.subjectTissue Microarraysen_US
dc.subjectSurvivalen_US
dc.subjectCarcinomasen_US
dc.subjectOncogeneen_US
dc.subjectProteinen_US
dc.titleAssociation of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu